Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Mais filtros

Filtros aplicados

Base de dados
Intervalo de ano de publicação
Viral Immunol ; 11(3): 109-17, 1998.
Artigo em Inglês | MedCarib | ID: med-1333


An improved vaccine is needed against Venezuelan equine encephalitis (VEE) virus because the existing live attenuated vaccine, TC-83, causes a high incidence of adverse effects, and the Formalin-inactivated vaccine, C-84, does not protect against airborne infection. A recombinant vaccine had previously been constructed in which the VEE structural proteins were expressed by vaccinia virus. Although protection against subcutaneous challenge with VEE was achieved, the vaccine had limited efficacy against aerosolized virus. We made a similar construct (WR100) and compared its performance as a vaccine: a synthetic promoter was inserted upstream of the VEE coding sequence to increase the amount of VEE proteins produced, and a single nucleotide in the E2 glycoprotein gene was altered to enhance immunogenicity. The WR103 virus expressed greater amounts of VEE proteins on the surface of infected cells than did WR100, and this difference was production. Sera from mice immunized with WR103 contained elevated levels of antibody to VEE, and enhanced protection against subcutaneous challenge with the pathogenic Trinidad donkey strain was achieved. This altered construct could form the basis for a better vaccine against VEE.(Au)

21003 , Feminino , Anticorpos Antivirais/sangue , Vírus da Encefalite Equina Venezuelana/imunologia , Encefalomielite Equina Venezuelana/prevenção & controle , Vacinas Sintéticas/imunologia , Vacinas Virais/imunologia , Substituição de Aminoácidos , Ensaio de Imunoadsorção Enzimática , Engenharia Genética , Camundongos , Camundongos Endogâmicos BALB C , Proteínas Recombinantes/imunologia , Vacinação , Vírus Vaccinia/genética , Vírus Vaccinia/metabolismo , Proteínas Virais/análise , Proteínas Virais/imunologia
Ciba Found Symp ; 187: 47-55, 1994.
Artigo em Inglês | MedCarib | ID: med-4730


Human T cell lymphotropic virus types I and II (HTLV-I/II) are endemic in certain areas of the world. The cause two life-threatening diseases, adult T cell leukaemia/lymphoma and tropical spastic paraparesis. A vaccine is needed because in developing countries there are no other feasible preventive interventions against these diseases and in Western countries intravenous drug users at high risk for HTLV-I and HTLV-II infections and the health workers in contact with such populations must be protected. We have developed a rat model in which we observed variations of susceptibility to viral infection between inbred strains, the most susceptible being Fischer F344, and the possibility of viral latency in the nervous system. We have prepared a recombinant adenovirus vector that expresses the HTLV-I envelope glycoprotein env in HeLa cells. A target human population in French Guyana, in which the prevalence rate reaches 5.6 percent in one ethnic group (Bonis), has been identified for possible intervention (AU)

21003 , Humanos , Vírus Linfotrópico T Tipo 1 Humano/imunologia , Infecções por HTLV-I/prevenção & controle , Vírus Linfotrópico T Tipo 2 Humano/imunologia , Infecções por HTLV-II/prevenção & controle , Vacinas Sintéticas/uso terapêutico , Vacinas Virais/uso terapêutico , Modelos Animais de Doenças , Estudos de Viabilidade , Leucemia-Linfoma de Células T do Adulto , Leucemia-Linfoma Linfoblástico de Células T Precursoras/prevenção & controle , Paraparesia Espástica Tropical/prevenção & controle
J Infect Dis ; 168(6): 1520-3, Dec. 1993.
Artigo em Inglês | MedCarib | ID: med-8336


To determine whether yellow fever (YF) vaccine administered in pregnancy causes fetal infection, women who were vaccinated during unrecognized pregnancy in a mass campaign in Trinidad were studied retrospectively. Maternal and cord or infant blood were tested for IgM and neutralizing antibodies to YF virus, indicating congenital infection. The infant, the first repotred case of YF virus infection after immunization in prgnancy, was delivered after an uncomplicated full-term pregnancy and appeared normal. Congenital dengue 1 infection may have occurred in another case. The frequency of fetal infection and adverse events after such exposure could not be estimated; however, the neurotropism of YF virus for the developing nervous system and the now documented possibility of trans-placental infection underscores the admonition that YF vaccination in pregnancy should be avoided (AU)

Humanos , Gravidez , Recém-Nascido , Feminino , Vacinas Virais/efeitos adversos , Febre Amarela/congênito , Reações Cruzadas , Vírus da Dengue/imunologia , Estudos Retrospectivos , Trinidad e Tobago/epidemiologia , Vacinas Virais/imunologia , Febre Amarela/epidemiologia , Febre Amarela/etiologia , Vírus da Febre Amarela/imunologia
In. Levett, Paul N; Fraser, Henry S; Hoyos, Michael D. Medicine and therapeutics update 1990: proceedings of Continuing Medical Education symposia in Barbados, November 1988 & June 1989. St. Michael, University of the West Indies, (Cave Hill). Faculty of Medical Sciences, 1990. p.34-41.
Monografia em Inglês | MedCarib | ID: med-15007


This article looks at the history, development, progress and research of the Human Immunodeficiency Virus (HIV) which causes AIDS. The author reports of the ongoing research into a vaccine for HIV, he examines the viral life cycle and indicates the points at which the virus can be attacked, and classifies antiviral strategies

HIV , Infecções por HIV/classificação , Infecções por HIV/diagnóstico , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , Infecções por HIV/história , Infecções por HIV/terapia , HIV-2/análise , HIV-2/classificação , HIV-2/crescimento & desenvolvimento , HIV-2/isolamento & purificação , HIV-2/patogenicidade , HIV-1/análise , HIV-1/classificação , HIV-1/crescimento & desenvolvimento , HIV-1/isolamento & purificação , HIV-1/patogenicidade , Sistema Imunitário/patologia , HIV , Complexo Relacionado com a AIDS/diagnóstico , Complexo Relacionado com a AIDS/tratamento farmacológico , Complexo Relacionado com a AIDS/etnologia , Complexo Relacionado com a AIDS/etiologia , Complexo Relacionado com a AIDS/história , Complexo Relacionado com a AIDS/terapia , Complexo Relacionado com a AIDS/transmissão , Vacinas/administração & dosagem , Vacinas/efeitos adversos , Vacinas/análise , Vacinas/classificação , Vacinas/diagnóstico , Vacinas/imunologia , Vacinas/farmacologia , Vacinas Virais/administração & dosagem , Vacinas Virais/efeitos adversos , Vacinas Virais/classificação , Vacinas Virais/diagnóstico , Vacinas Virais/farmacologia , Vacinas Virais/uso terapêutico , Soropositividade para HIV , Produtos do Gene tat/análise , Produtos do Gene tat/classificação , Produtos do Gene tat/diagnóstico , Produtos do Gene tat/uso terapêutico
Lancet ; 3(801): 457-8, Mar. 3 1973.
Artigo em Inglês | MedCarib | ID: med-14838


A study of serum-samples from immunised individuals showed that administration of yellow-fever and cholera vaccine, simultaneously or one to three weeks apart, reduced the vibriocidal and yellow-fever-virus-neutralising antibody titres (AU)

Humanos , Cólera/prevenção & controle , Vacinas contra Cólera/administração & dosagem , Vacinas Virais/administração & dosagem , Febre Amarela/prevenção & controle , Anticorpos/análise , Formação de Anticorpos/efeitos dos fármacos , Cólera/imunologia , Fatores de Tempo , Vacinação , Vibrio cholerae/imunologia , Febre Amarela/imunologia , Vírus da Febre Amarela/imunologia
J Hyg ; 68(3): 505-10, Sept. 1970.
Artigo em Inglês | MedCarib | ID: med-14870


This report summarizes closed, family, and open studies conducted sequentially over a 10 month period with the Cendehill rubella virus vaccine in more than 16,000 children and adolescents. This strain of rubella was attenuated by serial propogation on primary rabbit kidney cell cultures. Inoculation of the Cendehill vaccine produced seroconversion in 97 percent of the 3589 susceptible (seronegative) vaccinated persons. There was no spread of the virus to susceptible controls living in close contact with those vaccinated. The vaccine was well tolerated. No arthritis or arthralgia occured in 860 female subjects 13-18 years of age who were included in the study. The Cendehill vaccine would appear to meet the requirements of an acceptable vaccine (Summary)

Humanos , Pré-Escolar , Criança , Adolescente , Adulto , Masculino , Feminino , Vírus da Rubéola/imunologia , Vacinas Virais , Formação de Anticorpos , Seguimentos , Testes de Inibição da Hemaglutinação , Placebos , Rubéola (Sarampo Alemão)/prevenção & controle , Vacina contra Rubéola , Vacinação
Am J Trop Med Hyg ; 15(2): 219-26, Mar. 1966.
Artigo em Inglês | MedCarib | ID: med-9561


A method for producing large volumes of mouse ascitic fluids with high viral antibody titers by the use of adjuvant in combination with Sarcoma 180 cells is described. Ascitic fluids so produced reacted specifically with the viruses to which they were prepared. In cross complement-fixation and hemagglutination-inhibition tests, none of 26 ascitic fluids prepared to individual viruses and of nine polyvalent ascitic fluids reacted with antigens outside the recongnized or artificial grouping. Satisfactory neutralization indices were obtained with the ascitic fluids tested.(AU)

Camundongos , 21003 , Adjuvantes Imunológicos , Arbovirus/imunologia , Ascite , Sarcoma 180 , Testes de Fixação de Complemento , Testes de Inibição da Hemaglutinação , Soros Imunes , Testes de Neutralização , Vacinas Virais